Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.
| Title: | Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. |
|---|---|
| Authors: | YUTO YASUDA, YASUYO NISHIKAWA, YUICHI SAKAMORI, MAKOTO TERAO, KENTARO HASHIMOTO, TOMOKO FUNAZO, TAKASHI NOMIZO, TAKAHIRO TSUJI, HIRONORI YOSHIDA, HIROKI NAGAI, HIROAKI OZASA, TOYOHIRO HIRAI, YOUNG HAK KIM |
| Source: | Molecular & Clinical Oncology; 2017, Vol. 7 Issue 2, p295-297, 3p |
| Subject Terms: | DESENSITIZATION (Psychotherapy), ANAPLASTIC lymphoma kinase, CRIZOTINIB |
| Abstract: | Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth-line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib-induced hepatitis. [ABSTRACT FROM AUTHOR] |
| Copyright of Molecular & Clinical Oncology is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Complementary Index |
| FullText | Links: – Type: pdflink Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=20499450&ISBN=&volume=7&issue=2&date=20170801&spage=295&pages=295-297&title=Molecular & Clinical Oncology&atitle=Successful%20oral%20desensitization%20with%20crizotinib%20after%20crizotinib-induced%20hepatitis%20in%20an%20anaplastic%20lymphoma%20kinase-rearranged%20non-small-cell%20lung%20cancer%20patient%3A%20A%20case%20report.&aulast=YUTO%20YASUDA&id=DOI:10.3892/mco.2017.1310 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: edb DbLabel: Complementary Index An: 123964374 RelevancyScore: 846 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 845.668579101563 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22YUTO+YASUDA%22">YUTO YASUDA</searchLink><br /><searchLink fieldCode="AR" term="%22YASUYO+NISHIKAWA%22">YASUYO NISHIKAWA</searchLink><br /><searchLink fieldCode="AR" term="%22YUICHI+SAKAMORI%22">YUICHI SAKAMORI</searchLink><br /><searchLink fieldCode="AR" term="%22MAKOTO+TERAO%22">MAKOTO TERAO</searchLink><br /><searchLink fieldCode="AR" term="%22KENTARO+HASHIMOTO%22">KENTARO HASHIMOTO</searchLink><br /><searchLink fieldCode="AR" term="%22TOMOKO+FUNAZO%22">TOMOKO FUNAZO</searchLink><br /><searchLink fieldCode="AR" term="%22TAKASHI+NOMIZO%22">TAKASHI NOMIZO</searchLink><br /><searchLink fieldCode="AR" term="%22TAKAHIRO+TSUJI%22">TAKAHIRO TSUJI</searchLink><br /><searchLink fieldCode="AR" term="%22HIRONORI+YOSHIDA%22">HIRONORI YOSHIDA</searchLink><br /><searchLink fieldCode="AR" term="%22HIROKI+NAGAI%22">HIROKI NAGAI</searchLink><br /><searchLink fieldCode="AR" term="%22HIROAKI+OZASA%22">HIROAKI OZASA</searchLink><br /><searchLink fieldCode="AR" term="%22TOYOHIRO+HIRAI%22">TOYOHIRO HIRAI</searchLink><br /><searchLink fieldCode="AR" term="%22YOUNG+HAK+KIM%22">YOUNG HAK KIM</searchLink> – Name: TitleSource Label: Source Group: Src Data: Molecular & Clinical Oncology; 2017, Vol. 7 Issue 2, p295-297, 3p – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22DESENSITIZATION+%28Psychotherapy%29%22">DESENSITIZATION (Psychotherapy)</searchLink><br /><searchLink fieldCode="DE" term="%22ANAPLASTIC+lymphoma+kinase%22">ANAPLASTIC lymphoma kinase</searchLink><br /><searchLink fieldCode="DE" term="%22CRIZOTINIB%22">CRIZOTINIB</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth-line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib-induced hepatitis. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Group: Ab Data: <i>Copyright of Molecular & Clinical Oncology is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=123964374 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3892/mco.2017.1310 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 3 StartPage: 295 Subjects: – SubjectFull: DESENSITIZATION (Psychotherapy) Type: general – SubjectFull: ANAPLASTIC lymphoma kinase Type: general – SubjectFull: CRIZOTINIB Type: general Titles: – TitleFull: Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: YUTO YASUDA – PersonEntity: Name: NameFull: YASUYO NISHIKAWA – PersonEntity: Name: NameFull: YUICHI SAKAMORI – PersonEntity: Name: NameFull: MAKOTO TERAO – PersonEntity: Name: NameFull: KENTARO HASHIMOTO – PersonEntity: Name: NameFull: TOMOKO FUNAZO – PersonEntity: Name: NameFull: TAKASHI NOMIZO – PersonEntity: Name: NameFull: TAKAHIRO TSUJI – PersonEntity: Name: NameFull: HIRONORI YOSHIDA – PersonEntity: Name: NameFull: HIROKI NAGAI – PersonEntity: Name: NameFull: HIROAKI OZASA – PersonEntity: Name: NameFull: TOYOHIRO HIRAI – PersonEntity: Name: NameFull: YOUNG HAK KIM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2017 Type: published Y: 2017 Identifiers: – Type: issn-print Value: 20499450 Numbering: – Type: volume Value: 7 – Type: issue Value: 2 Titles: – TitleFull: Molecular & Clinical Oncology Type: main |
| ResultId | 1 |